OBJECTIVES: DLBCL is the most common form of Non-Hodgkin Lymphoma. Most DLBCL is successfully treated with immunochemotherapy resulting in long term remission. Although there is some evidence on the impact of therapy on quality of life (QoL), data are lacking on the long term impact of previous DLBCL diagnosis and treatment on QoL. The aim of this study was to describe the health state utility value and determinants of QoL in DLBCL patients in remission who are no longer receiving treatment. METHODS: UK patients in first remission (>12 months) from DLBCL were recruited via a lymphoma patient organisation and a patient recruitment agency in this cross-sectional, observational, questionnaire based study [NCT02708732]. Utility scores were calculated from the EQ-5D-5L and quality of life was assessed using the FACT-Lym. Utility scores were compared to published UK population norms. RESULTS:  91 patients (69% female) were recruited into the study with a mean age of 50 years (range= 21-77). The mean utility for the patient population was 0.78 (range -0.01-1.00; SD 0.24). Patients most frequently reported problems in the EQ-5D Pain and Discomfort and Anxiety and Depression domains. The mean FACT-Lym score was 114 points (SD 31.37; maximum possible score 168). The items of the FACT-Lym Lymphoma-specific domain with the worst scores related to tiredness, worry and emotional distress and pain. CONCLUSIONS: Our study describes the real world utility values reported by DLBCL patients in first remission. People in this study report decrements in QoL. They, although deemed to be in clinical remission, are affected by tiredness, worry and pain. Although people with DLBCL have a high chance of a full cure after treatment, this is evidence that quality of life, particularly emotional functioning, is impacted during remission. Further analyses will be conducted to understand characteristics impacting responses and utility values in relation to age adjusted norms.